Immunological headgear: antiviral immune responses protect against neuroinvasive West Nile virus

Trends in Molecular Medicine

Volumn 14, Issue 7, 2008, Pages 286-294

  Klein, Robyn S ^a   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1Q; CYCLOPHOSPHAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERFERON RECEPTOR; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 1BETA; JANUS KINASE; MATRIX METALLOPROTEINASE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; STAT PROTEIN; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 3; UVOMORULIN; VIRUS PROTEIN; VIRUS RNA; WEST NILE VACCINE;

ADAPTIVE IMMUNITY; AUTOIMMUNITY; BLOOD BRAIN BARRIER; BRAIN REGION; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; RNA BINDING; SIGNAL TRANSDUCTION; SURVIVAL RATE; T LYMPHOCYTE; VIREMIA; VIRUS ENCEPHALITIS; VIRUS INFECTION; VIRUS LOAD; WEST NILE FLAVIVIRUS; X IRRADIATION;

ANIMALS; CENTRAL NERVOUS SYSTEM; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, INNATE; MODELS, IMMUNOLOGICAL; WEST NILE FEVER; WEST NILE VIRUS;

WEST NILE VIRUS;

EID: 46049095465     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2008.05.004     Document Type: Review

References (121)

1. Hayes E.B., et al. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg. Infect. Dis. 11 (2005) 1174-1179
2. Sejvar J.J., et al. Neurologic manifestations and outcome of West Nile virus infection. J. Am. Med. Assoc. 290 (2003) 511-515
3. Beasley D.W. Recent advances in the molecular biology of West Nile virus. Curr. Mol. Med. 5 (2005) 835-850
4. Komar N. West Nile viral encephalitis. Rev. Sci. Tech. 19 (2000) 166-176
5. Garcia-Tapia D., et al. West Nile virus encephalitis: sequential histopathological and immunological events in a murine model of infection. J. Neurovirol. 13 (2007) 130-138
6. Byrne S.N., et al. Interleukin-1beta but not tumor necrosis factor is involved in West Nile virus-induced Langerhans cell migration from the skin in C57BL/6 mice. J. Invest. Dermatol. 117 (2001) 702-709
7. Liu W.J., et al. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. J. Virol. 80 (2006) 2396-2404
8. Scholle F., and Mason P.W. West Nile virus replication interferes with both poly(I:C)-induced interferon gene transcription and response to interferon treatment. Virology 342 (2005) 77-87
9. Diamond M.S., et al. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198 (2003) 1853-1862
10. Arjona A., et al. Abrogation of macrophage migration inhibitory factor decreases West Nile virus lethality by limiting viral neuroinvasion. J. Clin. Invest. 117 (2007) 3059-3066
11. Diamond M.S., et al. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J. Virol. 77 (2003) 2578-2586
12. Johnston L.J., et al. Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J. Invest. Dermatol. 114 (2000) 560-568
13. Kawai T., and Akira S. Antiviral signaling through pattern recognition receptors. J. Biochem. (Tokyo) 141 (2007) 137-145
14. Kato H., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441 (2006) 101-105
15. Fredericksen B.L., et al. Establishment and maintenance of the innate antiviral response to West Nile Virus involves both RIG-I and MDA5 signaling through IPS-1. J. Virol. 82 (2007) 609-616
16. Fredericksen B.L., and Gale Jr. M. West Nile virus evades activation of interferon regulatory factor 3 through RIG-I-dependent and -independent pathways without antagonizing host defense signaling. J. Virol. 80 (2006) 2913-2923
17. Fredericksen B.L., et al. The host response to West Nile virus infection limits viral spread through the activation of the interferon regulatory factor 3 pathway. J. Virol. 78 (2004) 7737-7747
18. Gitlin L., et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 8459-8464
19. Bourne N., et al. Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. J. Virol. 81 (2007) 9100-9108
20. Daffis S., et al. Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog. 3 (2007) e106
21. Silva M.C., et al. Differential activation of human monocyte-derived and plasmacytoid dendritic cells by West Nile virus generated in different host cells. J. Virol. 81 (2007) 13640-13648
22. Hoshino K., et al. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 440 (2006) 949-953
23. Wang T., et al. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat. Med. 10 (2004) 1366-1373
24. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5 (2005) 375-386
25. Gilfoy F.D., and Mason P.W. West Nile virus-induced interferon production is mediated by the double-stranded RNA-dependent protein kinase PKR. J. Virol. 81 (2007) 11148-11158
26. Perelygin A.A., et al. Positional cloning of the murine flavivirus resistance gene. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 9322-9327
27. Samuel M.A., and Diamond M.S. Pathogenesis of West Nile virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J. Virol. 80 (2006) 9349-9360
28. Scherbik S.V., et al. RNase L plays a role in the antiviral response to West Nile virus. J. Virol. 80 (2006) 2987-2999
29. Samuel M.A., and Diamond M.S. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J. Virol. 79 (2005) 13350-13361
30. Lobigs M., et al. Role of type I and type II interferon responses in recovery from infection with an encephalitic flavivirus. J. Gen. Virol. 84 (2003) 567-572
31. Liu W.J., et al. Inhibition of interferon signaling by the New York 99 strain and Kunjin subtype of West Nile virus involves blockage of STAT1 and STAT2 activation by nonstructural proteins. J. Virol. 79 (2005) 1934-1942
32. Evans J.D., and Seeger C. Differential effects of mutations in NS4B on West Nile virus replication and inhibition of interferon signaling. J. Virol. 81 (2007) 11809-11816
33. Guo J.T., et al. West Nile virus inhibits the signal transduction pathway of alpha interferon. J. Virol. 79 (2005) 1343-1350
34. Keller B.C., et al. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. J. Virol. 80 (2006) 9424-9434
35. Mackenzie J.M., et al. Cholesterol manipulation by West Nile virus perturbs the cellular immune response. Cell Host Microbe 2 (2007) 229-239
36. Poccia F., et al. Antiviral reactivities of gammadelta T cells. Microbes Infect. 7 (2005) 518-528
37. Shrestha B., et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J. Virol. 80 (2006) 5338-5348
38. Wang T., et al. Gamma delta T cells facilitate adaptive immunity against West Nile virus infection in mice. J. Immunol. 177 (2006) 1825-1832
39. Carroll M.C. The complement system in regulation of adaptive immunity. Nat. Immunol. 5 (2004) 981-986
40. Mehlhop E., and Diamond M.S. Protective immune responses against West Nile virus are primed by distinct complement activation pathways. J. Exp. Med. 203 (2006) 1371-1381
41. Mehlhop E., et al. Complement activation is required for induction of a protective antibody response against West Nile virus infection. J. Virol. 79 (2005) 7466-7477
42. Cardosa M.J., et al. Complement receptor mediates enhanced flavivirus replication in macrophages. J. Exp. Med. 158 (1983) 258-263
43. Cardosa M.J., et al. Interaction of West Nile virus with primary murine macrophages: role of cell activation and receptors for antibody and complement. J. Virol. 57 (1986) 952-959
44. Iankov I.D., et al. Immunoglobulin G antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J. Virol. 80 (2006) 8530-8540
45. Feng J.Q., et al. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J. Virol. 76 (2002) 1369-1378
46. Beebe D.P., and Cooper N.R. Neutralization of vesicular stomatitis virus (VSV) by human complement requires a natural IgM antibody present in human serum. J. Immunol. 126 (1981) 1562-1568
47. Meyer K., et al. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J. Virol. 76 (2002) 2150-2158
48. Aasa-Chapman M.M., et al. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J. Virol. 79 (2005) 2823-2830
49. Mehlhop E., et al. Complement protein C1q inhibits antibody-dependent enhancement of flavivirus infection in an IgG subclass-specific manner. Cell Host Microbe 2 (2007) 417-426
50. Katz L.M., and Bianco C. West Nile virus. N. Engl. J. Med. 349 (2003) 1873-1874
51. + T cell-mediated immune responses in West Nile virus (Sarafend strain) encephalitis are independent of gamma interferon. J. Gen. Virol. 87 (2006) 3599-3609
52. + T cells mediate recovery and immunopathology in West Nile virus encephalitis. J. Virol. 77 (2003) 13323-13334
53. Wang T., et al. IFN-gamma-producing gamma delta T cells help control murine West Nile virus infection. J. Immunol. 171 (2003) 2524-2531
54. + T cells in control of West Nile virus infection. J. Virol. 78 (2004) 8312-8321
55. Chan-Tack K.M., and Forrest G. West nile virus meningoencephalitis and acute flaccid paralysis after infliximab treatment. J. Rheumatol. 33 (2006) 191-192
56. Kumar D., and Humar A. Emerging viral infections in transplant recipients. Curr. Opin. Infect. Dis. 18 (2005) 337-341
57. Mateo R., et al. Effects of immunosuppression on West Nile virus infection in hamsters. Am. J. Trop. Med. Hyg. 75 (2006) 356-362
58. Diamond M.S., et al. Innate and adaptive immune responses determine protection against disseminated infection by West Nile encephalitis virus. Viral Immunol. 16 (2003) 259-278
59. Engle M.J., and Diamond M.S. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J. Virol. 77 (2003) 12941-12949
60. Colombage G., et al. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250 (1998) 151-163
61. Oliphant T., et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat. Med. 11 (2005) 522-530
62. Kaufmann B., et al. West Nile virus in complex with the Fab fragment of a neutralizing monoclonal antibody. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 12400-12404
63. Nybakken G.E., et al. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437 (2005) 764-769
64. Chung K.M., et al. Antibodies against West Nile virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J. Virol. 80 (2006) 1340-1351
65. Roehrig J.T., et al. Antibody prophylaxis and therapy for flavivirus encephalitis infections. Ann. N. Y. Acad. Sci. 951 (2001) 286-297
66. Roehrig J.T., et al. Identification of epitopes on the E glycoprotein of Saint Louis encephalitis virus using monoclonal antibodies. Virology 128 (1983) 118-126
67. Beasley D.W., and Barrett A.D. Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein. J. Virol. 76 (2002) 13097-13100
68. Sanchez M.D., et al. Characterization of neutralizing antibodies to West Nile virus. Virology 336 (2005) 70-82
69. Beasley D.W., et al. Use of a recombinant envelope protein subunit antigen for specific serological diagnosis of West Nile virus infection. J. Clin. Microbiol. 42 (2004) 2759-2765
70. Sanchez M.D., et al. The neutralizing antibody response against West Nile virus in naturally infected horses. Virology 359 (2007) 336-348
71. Crill W.D., and Chang G.J. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J. Virol. 78 (2004) 13975-13986
72. Stiasny K., et al. Cryptic properties of a cluster of dominant flavivirus cross-reactive antigenic sites. J. Virol. 80 (2006) 9557-9568
73. Oliphant T., et al. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J. Virol. 80 (2006) 12149-12159
74. Gajdosova E., et al. Cell-mediated immunity in flavivirus infections. I. Induction of cytotoxic T lymphocytes in mice by an attenuated virus from the tick-borne encephalitis complex and its group-reactive character. Acta Virol. 25 (1981) 10-18
75. Kelkar S.D., et al. Development of in vitro correlate of cell mediated immunity following Japanese encephalitis inactivated vaccine among laboratory personnel. Indian J. Med. Res. 83 (1986) 104-107
76. Kesson A.M., et al. The primary in vivo murine cytotoxic T cell response to the flavivirus, West Nile. J. Gen. Virol. 68 (1987) 2001-2006
77. Kulkarni A.B., et al. In vitro T-cell proliferative response to the flavivirus, West Nile. Viral Immunol. 4 (1991) 73-82
78. Camenga D.L., et al. Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J. Infect. Dis. 130 (1974) 634-641
79. Elftman M.D., et al. Corticosterone impairs dendritic cell maturation and function. Immunology 122 (2007) 279-290
80. Wonnacott K.M., and Bonneau R.H. The effects of stress on memory cytotoxic T lymphocyte-mediated protection against herpes simplex virus infection at mucosal sites. Brain Behav. Immun. 16 (2002) 104-117
81. Ben-Nathan D., and Feuerstein G. The influence of cold or isolation stress on resistance of mice to West Nile virus encephalitis. Experientia 46 (1990) 285-290
82. Jung Y., et al. Regulation of SDF-1 (CXCL12) production by osteoblasts; a possible mechanism for stem cell homing. Bone 38 (2006) 497-508
83. Getts D.R., et al. Role of IFN-gamma in an experimental murine model of West Nile virus-induced seizures. J. Neurochem. 103 (2007) 1019-1030
84. Wang Y., et al. Exocytosis and Fas mediated cytolytic mechanisms exert protection from West Nile virus induced encephalitis in mice. Immunol. Cell Biol. 82 (2004) 170-173
85. + T-cell responses are required for clearance of West Nile virus from the central nervous system. J. Virol. 80 (2006) 12060-12069
86. + T cells require perforin to clear West Nile virus from infected neurons. J. Virol. 80 (2006) 119-129
87. Samuel M.A., et al. Axonal transport mediates West Nile virus entry into the central nervous system and induces acute flaccid paralysis. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 17140-17145
88. Yu X., et al. Macrophage migration inhibitory factor induces MMP-9 expression in macrophages via the MEK-ERK MAP kinase pathway. J. Interferon Cytokine Res. 27 (2007) 103-109
89. Gidday J.M., et al. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H558-H568
90. + T cells into the brain during chronic infection with Toxoplasma gondii. J. Interferon Cytokine Res. 27 (2007) 329-338
91. Ben-Nathan D., et al. West Nile virus neuroinvasion and encephalitis induced by macrophage depletion in mice. Arch. Virol. 141 (1996) 459-469
92. Samuel M.A., et al. Caspase-3 dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis. J. Virol. 81 (2006) 2614-2623
93. Shrestha B., et al. Infection and injury of neurons by West Nile encephalitis virus. J. Virol. 77 (2003) 13203-13213
94. Hunsperger E.A., and Roehrig J.T. Temporal analyses of the neuropathogenesis of a West Nile virus infection in mice. J. Neurovirol. 12 (2006) 129-139
95. Wacher C., et al. Coordinated regulation and widespread cellular expression of interferon-stimulated genes (ISG) ISG-49, ISG-54, and ISG-56 in the central nervous system after infection with distinct viruses. J. Virol. 81 (2007) 860-871
96. + T-cell recruitment and control of West Nile virus encephalitis. J. Virol. 79 (2005) 11457-11466
97. Zhang B., et al. CXCR3 mediates region-specific antiviral T cell trafficking within the central nervous system during West Nile virus encephalitis. J. Immunol. 180 (2008) 2641-2649
98. Glass W.G., et al. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J. Exp. Med. 202 (2005) 1087-1098
99. Shirato K., et al. Different chemokine expression in lethal and non-lethal murine West Nile virus infection. J. Med. Virol. 74 (2004) 507-513
100. Glass W.G., et al. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J. Exp. Med. 203 (2006) 35-40
101. Lim J.K., et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J. Infect. Dis. 197 (2008) 262-265
102. Bouffard J.P., et al. Neuropathology of the brain and spinal cord in human West Nile virus infection. Clin. Neuropathol. 23 (2004) 59-61
103. McCandless E.E., et al. CXCL12 limits inflammation by localizing mononuclear infiltrates to the perivascular space during experimental autoimmune encephalomyelitis. J. Immunol. 177 (2006) 8053-8064
104. McCandless E.E., et al. Pathologic expression of CXCL12 at the blood-brain barrier correlates with severity of multiple sclerosis. Am. J. Pathol. 172 (2008) 799-808
105. + T cell accumulation in rheumatoid arthritis synovium. J. Immunol. 165 (2000) 6590-6598
106. + T cell adhesion to endothelium. J. Neuroimmunol. 134 (2003) 166-178
107. Becher B., et al. The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J. Exp. Med. 193 (2001) 967-974
108. Gimenez M.A., et al. A tumor necrosis factor receptor 1-dependent conversation between central nervous system-specific T cells and the central nervous system is required for inflammatory infiltration of the spinal cord. Am. J. Pathol. 168 (2006) 1200-1209
109. Howard L.M., et al. Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis. J. Clin. Invest. 103 (1999) 281-290
110. + T cells into the brain and protection against West Nile virus encephalitis. J. Virol. 81 (2007) 9801-9811
111. Ben-Nathan D., et al. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J. Infect. Dis. 188 (2003) 5-12
112. Hamdan A., et al. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl. Infect. Dis. 4 (2002) 160-162
113. Seino K.K., et al. Comparative efficacies of three commercially available vaccines against West Nile virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model. Clin. Vaccine Immunol. 14 (2007) 1465-1471
114. Long M.T., et al. Efficacy, duration, and onset of immunogenicity of a West Nile virus vaccine, live Flavivirus chimera, in horses with a clinical disease challenge model. Equine Vet. J. 39 (2007) 491-497
115. Martin J.E., et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J. Infect. Dis. 196 (2007) 1732-1740
116. Zohrabian A., et al. Cost-effectiveness of West Nile virus vaccination. Emerg. Infect. Dis. 12 (2006) 375-380
117. Dheen S.T., et al. Microglial activation and its implications in the brain diseases. Curr. Med. Chem. 14 (2007) 1189-1197
118. Ghoshal A., et al. Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia 55 (2007) 483-496
119. Heppner F.L., et al. Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11 (2005) 146-152
120. Nargi-Aizenman J.L., et al. Glutamate receptor antagonists protect from virus-induced neural degeneration. Ann. Neurol. 55 (2004) 541-549
121. Mishra M.K., et al. Neuroprotection conferred by astrocytes is insufficient to protect animals from succumbing to Japanese encephalitis. Neurochem. Int. 50 (2007) 764-773